FIELD: biotechnology.
SUBSTANCE: group of inventions relates to compounds representing monoadducts of tumor necrosis factor alpha (TNF-alpha) and aminobisphosphonate, having high affinity to bone tissue, and can be used in biotechnologies, pharmacology and medicine. Anti-tumor means include alendronic acid and human tumor necrosis factor alpha (TNF-alpha), connected to each other in form of monoadduct with high affinity to hydroxyapatite.
EFFECT: creation of products based on TNF-alpha and bisphosphonate with properties of vector molecules directed against tumor metastases of bone tissue.
5 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREPARING ANTINEOPLASTIC DRUG AGAINST BONE METASTASES IN FORM OF CONJUGATE OF PROTEIN-CYTOKINE AND AMINOBISPHOSPHONATE | 2016 |
|
RU2631486C1 |
| TARGETED COLONY-STIMULATING AGENT | 2020 |
|
RU2749509C1 |
| ANTITUMOUR AGENT BASED ON BIODEGRADABLE NANOPARTICLES CARRYING A RECOMBINANT HUMAN TUMOR NECROSIS FACTOR ALPHA | 2018 |
|
RU2691938C1 |
| METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2169006C1 |
| ANTICANCER DRUG BASED ON NANOPARTICLES BEARING RECOMBINANT HUMAN TUMOUR NECROSIS FACTOR ALPHA | 2008 |
|
RU2386447C1 |
| METHOD FOR PREDICTING CLINICAL DEVELOPMENT COURSE OF UVEAL MELANOMA | 1998 |
|
RU2146823C1 |
| ANTITUMOR AGENT | 1998 |
|
RU2136278C1 |
| COMBINED CELL TRANSPLANT BASED ON LYMPHOKINE-ACTIVATED KILLERS AND DENDRITE CELLS, METHOD FOR PRODUCTION THEREOF AND METHOD FOR TREATMENT AND PROPHYLAXIS OF MALIGNANT, INFECTIVE DISEASES AND IMMUNODEFICIENT CONDITIONS | 2006 |
|
RU2309753C1 |
| IMMUNOTHERAPY METHOD FOR TREATING PATIENTS FOR SOLID TUMORS BY APPLYING TUMOR LYSATE WITH BETALEUKINE ADJUVANT | 2004 |
|
RU2267326C2 |
| METHOD OF PRODUCING ANTIGEN-SPECIFIC CYTOTOXIC CELLS HAVING ACTIVITY AGAINST BREAST CANCER CELLS | 2013 |
|
RU2596920C2 |
